The DOI matches its Crossref record, with a small difference in title or year; 21 of the 22 references it cites were found in a registry or an index.
Association Between Sitagliptin Use and Heart Failure Hospitalization and Related Outcomes in Type 2 Diabetes Mellitus: Secondary Analysis of a Randomized Clinical Trial
Open accessAbstract
IMPORTANCE: Previous trial results have suggested that dipeptidyl peptidase 4 inhibitor (DPP4i) use might increase heart failure (HF) risk in type 2 diabetes mellitus (T2DM). The DPP4i sitagliptin has been shown to be noninferior to placebo with regard to primary and secondary composite atherosclerotic cardiovascular (CV) outcomes in the Trial Evaluating Cardiovascular Outcomes With Sitagliptin (TECOS). OBJECTIVE: To assess the association of sitagliptin use with hospitalization for HF (hHF) and related outcomes. DESIGN, SETTING, AND PARTICIPANTS: TECOS was a randomized, double-blind, placebo-controlled study evaluating the CV safety of sitagliptin vs placebo, each added to usual antihyperglycemic therapy and CV care among patients with T2DM and prevalent atherosclerotic vascular disease. The median follow-up was 2.9 years. The setting was 673 sites in 38 countries. Participants included 14 671 patients with T2DM and atherosclerotic vascular disease. The study dates were December 2008 through March 2015. INTERVENTIONS: Patients were randomized to sitagliptin vs placebo added to standard care. MAIN OUTCOMES AND MEASURES: Prespecified secondary analyses compared the effect on hHF, hHF or CV death, and hHF or all-cause death composite outcomes overall and in prespecified subgroups. Supportive analyses included total hHF events (first plus recurrent) and post-hHF death. Meta-analyses evaluated DPP4i effects on hHF and on hHF or CV death. RESULTS: Of 14 671 patients, 7332 were randomized to sitagliptin and 7339 to placebo. Hospitalization for HF occurred in 3.1% (n = 228) and 3.1% (n = 229) of the sitagliptin and placebo groups, respectively (unadjusted hazard ratio, 1.00; 95% CI, 0.83-1.19). There was also no difference in total hHF events between the sitagliptin (n = 345) and placebo (n = 347) groups (unadjusted hazard ratio, 1.00; 95% CI, 0.80-1.25). Post-hHF all-cause death was similar in the sitagliptin and placebo groups (29.8% vs 28.8%, respectively), as was CV death (22.4% vs 23.1%, respectively). No heterogeneity for the effect of sitagliptin on hHF was observed in subgroup analyses across 21 factors (P > .10 for all interactions). Meta-analysis of the hHF results from the 3 reported DPP4i CV outcomes trials revealed moderate heterogeneity (I2 = 44.9, P = .16). CONCLUSIONS AND RELEVANCE: Sitagliptin use does not affect the risk for hHF in T2DM, both overall and among high-risk patient subgroups. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00790205.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“These observations led to the development and regulatory filing of prospective HF analysis plans for the TECOS (Trial Evaluating Cardiovascular Outcomes with Sitagliptin) and CARMELINA (Cardiovascular and Renal Microvascular Outcome Study With Linagliptin in Patients With Type 2 Diabetes Mellitus) trials, each of which revealed no increased risk of HF with either sitagliptin or linagliptin”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [178]
In the citing paper
“Sitagliptin and linagliptin had a neutral effect.174,[178][179][180]”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [178]
In the citing paper
“Likewise, sitagliptin in the TECOS trial had no signal of excess rates of HF. 18,185”
From Type 2 diabetes mellitus and heart failure: A position statement from the Heart Failure Association of the European Society of Cardiology (2018) · cites this paper as [185]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cox’s regression model for counting processes: A large sample study
Andersen, P. K., & Gill, R. D. (1982) · The Annals of Statistics · doi:10.1214/aos/1176345976 · Cited by 4,419
Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus
Scirica, B. M., Bhatt, D. L., Braunwald, E., Steg, P. G., Davidson, J., Hirshberg, B., Ohman, P., Frederich, R., Wiviott, S. D., Hoffman, E. B., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1307684 · Cited by 3,470
Self-citationEffect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes
Green, J. B., Bethel, M. A., Armstrong, P. W., Buse, J. B., Engel, S. S., Garg, J., Josse, R., Kaufman, K. D., Koglin, J., Korn, S., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501352 · Cited by 2,577
Self-citationAlogliptin after acute coronary syndrome in patients with type 2 diabetes
White, W. B., Cannon, C. P., Heller, S. R., Nissen, S. E., Bergenstal, R. M., Bakris, G. L., Perez, A. T., Fleck, P. R., Mehta, C. R., Kupfer, S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1305889 · Cited by 2,502
Zannad, F., Cannon, C. P., Cushman, W. C., Bakris, G. L., Menon, V., Perez, A. T., Fleck, P. R., Mehta, C. R., Kupfer, S., Wilson, C., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)62225-x · Cited by 757
Scirica, B. M., Braunwald, E., Raz, I., Cavender, M. A., Morrow, D. A., Jarolim, P., Udell, J. A., Mosenzon, O., Im, K., Umez-Eronini, A. A., et al. (2014) · Circulation · doi:10.1161/circulationaha.114.010389 · Cited by 725
Self-citationLago, R. M., Singh, P. P., & Nesto, R. W. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61514-1 · Cited by 710
Nissen, S. E. (2005) · JAMA · doi:10.1001/jama.294.20.joc50147 · Cited by 552
Cavender, M. A., Steg, P. G., Smith, S. C., Eagle, K., Ohman, E. M., Goto, S., Kuder, J., Im, K., Wilson, P. W. F., & Bhatt, D. L. (2015) · Circulation · doi:10.1161/circulationaha.114.014796 · Cited by 501
Heart failure: a cardiovascular outcome in diabetes that can no longer be ignored
McMurray, J. J. V., Gerstein, H. C., Holman, R. R., & Pfeffer, M. A. (2014) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(14)70031-2 · Cited by 305
Self-citationUdell, J. A., Cavender, M. A., Bhatt, D. L., Chatterjee, S., Farkouh, M. E., & Scirica, B. M. (2015) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(15)00044-3 · Cited by 254
Lincoff, A. M., Tardif, J., Schwartz, G. G., Nicholls, S. J., Rydén, L., Neal, B. C., Malmberg, K., Wedel, H., Buse, J. B., Henry, R. R., et al. (2014) · JAMA · doi:10.1001/jama.2014.3321 · Cited by 232
Self-citationGreen, J. B., Bethel, M. A., Paul, S. K., Ring, A., Kaufman, K. D., Shapiro, D. R., Califf, R. M., & Holman, R. R. (2013) · American Heart Journal · doi:10.1016/j.ahj.2013.09.003 · Cited by 136
Self-citationNew Drugs for the Treatment of Diabetes Mellitus
McGuire, D. K., & Inzucchi, S. E. (2008) · Circulation · doi:10.1161/circulationaha.107.704080 · Cited by 118
Self-citationDo Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Cause Heart Failure?
Clifton, P. M. (2014) · Clinical Therapeutics · doi:10.1016/j.clinthera.2014.10.009 · Cited by 55
Bethel, M. A., Green, J. B., Milton, J. E., Tajar, A., Engel, S. S., Califf, R. M., & Holman, R. R. (2015) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12441 · Cited by 45
Self-citationCardiovascular disease and type 2 diabetes mellitus: Regulating glucose and regulating drugs
Gore, M. O., & McGuire, D. K. (2009) · Current Cardiology Reports · doi:10.1007/s11886-009-0038-4 · Cited by 30
Self-citationMcGuire, D. K., Abdullah, S. M., See, R., Snell, P. G., McGavock, J., Szczepaniak, L. S., Ayers, C. R., Drazner, M. H., Khera, A., & de Lemos, J. A. (2010) · European Heart Journal · doi:10.1093/eurheartj/ehq228 · Cited by 29
Self-citationDPP-4 inhibitors and risk of heart failure EXAMINEd
Standl, E., & Schnell, O. (2015) · The Lancet · doi:10.1016/s0140-6736(15)60037-x · Cited by 22
Self-citationEffect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes
Pencina, M. J., Green, J. B., Kaufman, K. D., et al. (2021) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/qsms-h616 · Cited by 8
Self-citationFirst-time heart failure increases risk of diabetes mellitus
Holman, R. R. (2014) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2014.105 · Cited by 1
Self-citation
Flagged first, then by citations
1 of the 22 references couldn’t be matched to a known paper.
Research works printed but not linked: 1
- Bethel MA, Green JB, Milton J, et al; TECOS Executive Committee. Regional, age and sex differences in baseline characteristics of patients enrolled in the Trial Evaluating Cardiovascular Outcomes With Sitagliptin (TECOS). Diabetes Obes Metab. 2015;17(4):395-402.
Cited by
Sorted by citations
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629
Self-citation2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure
Heidenreich, P. A., Bozkurt, B., Aguilar, D., Allen, L. A., Byun, J. J., Colvin, M. M., Deswal, A., Drazner, M. H., Dunlay, S. M., Evers, L. R., et al. (2022) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.12.012 · Cited by 2,862
Heidenreich, P. A., Bozkurt, B., Aguilar, D., Allen, L. A., Byun, J. J., Colvin, M. M., Deswal, A., Drazner, M. H., Dunlay, S. M., Evers, L. R., et al. (2022) · Circulation · doi:10.1161/cir.0000000000001063 · Cited by 4,922
2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes.
Marx, N., Federici, M., Schütt, K., Müller-Wieland, D., Ajjan, R. A., Antunes, M. J., Christodorescu, R. M., Crawford, C., Di Angelantonio, E., Eliasson, B., et al. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad192 · Cited by 1,642
Self-citationRangaswami, J., Bhalla, V., Blair, J. E., Chang, T. I., Costa, S. P., Lentine, K. L., Lerma, E. V., Mezue, K. N., Molitch, M. E., Müllens, W., et al. (2019) · Circulation · doi:10.1161/cir.0000000000000664 · Cited by 1,535
Metadata
- Authors
- McGuire, D. K., Van de Werf, F., Armstrong, P. W., Standl, E., Koglin, J., Green, J. B., Bethel, M. A., Cornel, J. H., Lopes, R. D., Halvorsen, S., Ambrosio, G., Buse, J. B., Josse, R. G., Lachin, J. M., Pencina, M. J., Garg, J., Lokhnygina, Y., Holman, R. R., Peterson, E. D., & for the Trial Evaluating Cardiovascular Outcomes With Sitagliptin (TECOS) Study Group
- Affiliations
- The University of Texas Southwestern Medical Center (US)
- Department of Cardiovascular Sciences, University of Leuven, Leuven, Belgium
- University of Alberta (CA)
- Helmholtz Munich (DE)
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- Duke University (US)
- University of Oxford (GB)
- Medisch Centrum Alkmaar (NL)
- Division of Cardiology, Department of Medicine, Duke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina
- Oslo University Hospital (NO)
- University of Perugia (IT)
- University of North Carolina at Chapel Hill (US)
- St. Michael's Hospital (CA)
- George Washington University (US)
- Corresponding author
- McGuire, Darren K.
- ORCID
- Venue
- JAMA Cardiology
- Publisher
- American Medical Association (AMA)
- Published
- 2016-05-01
- Volume
- 1
- Issue
- 2
- Pages
- 126
- ISSN
- 2380-6583 (ISSN-L)
- OpenAlex
- W2335973015
- Cited by
- 217
- References
- 22
- Citations by year
- 2026: 5 · 2025: 4 · 2024: 9 · 2023: 8 · 2022: 15 · 2021: 16 · 2020: 31 · 2019: 31 · 2018: 46 · 2017: 38 · 2016: 13
- FWCI
- 42.85
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- JAMA Cardiology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- American Diabetes Association
- Bristol-Myers Squibb Foundation
- Amgen
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- GlaxoSmithKline
- Sanofi
- Gilead Sciences
- Intarcia Therapeutics
- Halozyme
- AstraZeneca HealthCare Foundation
- MacroGenics
- Novo Nordisk
- Astellas Pharma
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Function and Risk Factors
- Keywords
- sitagliptin, heart failure hospitalization, type 2 diabetes, DPP-4 inhibitors, cardiovascular safety, TECOS trial, atherosclerosis, cardiovascular mortality, all-cause mortality, glycemic control, antihyperglycemic therapy, subgroup analysis
- MeSH terms
- Sitagliptin Phosphate, Aged, Cardiovascular Diseases, Cause of Death, Diabetes Mellitus, Type 2, Female, Heart Failure, Hospitalization, Humans, Male, Middle Aged, Risk Factors, Prevalence, Hospital Mortality, Outcome Assessment, Health Care, Atherosclerosis, Dipeptidyl-Peptidase IV Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
